Is Rimonabant safe and effective for weight loss in overweight and obese people?
From: The Cochrane Collaboration
- Curioni, C., André, C., 2006. Rimonabant for overweight or obesity, in: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.
- 4 studies involved 6,625 people
- The paper is a systematic review / meta analysis of all relevant trials.
- This means that the data from all similar trials has been grouped together to form an overall outcome.
- Within 1 year, 20mg of Rimonabant produced a 4.9 kg greater reduction in body weight in comparison to a placebo.
- Improvements in waist circumference, cholesterol levels, triglyceride levels and blood pressure were also seen with Rimonabant.
- Rimonabant at 5 mg provided limited weight loss of only 1.3 kg greater than a placebo. No clinically relevant effects on plasma lipids (blood fats) and blood pressure were found.
- Rimonabant at 20 mg caused significantly more adverse effects, especially of nervous system, psychiatric or gastro-intestinal origin.
- Yes (without confidence)
- Despite a modest reduction in weight, the trial participants had to also follow a low-carb diet.
- There was a 40% drop-out rate from the trials. This may artificially improve the results coming from the Rimonabant participants.
- Rimonabant is not recommended for patients with severe depression and/or patients who are treated with antidepressive medications. Rimonabant is furthermore not recommended for patients with other untreated psychiatric conditions.